HER2-Positive Breast Cancer | Clinical

April 15, 2021

In patients with breast cancer, who were predominantly hormone receptor–positive, 37.8% had a conversion to HER2-positive status that led to significant benefit from frontline treatment with taxane-trastuzumab with or without pertuzumab.

April 14, 2021

Sara A. Hurvitz, MD, discusses sequencing the current therapies for patients with HER2-positive breast cancer.

April 12, 2021

In the phase 2 MutHER study, the combination of neratinib and fulvestrant demonstrated activity in heavily pretreated patients with estrogen receptor-positive, metastatic breast cancer, but the clinical benefit rate did not meet the predefined efficacy criteria.

March 30, 2021

March 30, 2021

Experts in breast cancer review clinical cases, discuss individualized treatment options and key clinical trials.

March 29, 2021

Debu Tripathy, MD, discusses the role that margetuximab will have in the field of HER2-positive metastatic breast cancer now that it is approved by the FDA.

March 29, 2021

In an interview with Targeted Oncology, Erika P. Hamilton, MD, explained how hormone receptor status in patients with HER2-positive breast cancer was affected by treatment with the HER2CLIMB regimen of tucatinib plus trastuzumab and capecitabine.

March 27, 2021

Positive efficacy and safety results observed with the proposed trastuzumab biosimilar, EG12014 in HER2-positive early breast cancer, has led the developer to plan regulatory filings in the United States, Europe, and China.

March 12, 2021

In an interview with Ecaterina Ileana Dumbrava, MD, discussed the ongoing study of BDC-1001 alone and in combination with an immune checkpoint inhibitor for the treatment of HER2-positive breast cancer and other solid tumors.

March 11, 2021

In an interview with Targeted Oncology, Joyce O’Shaughnessy, MD, chair of Breast Cancer Research and chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center of Texas Oncology, discussed the CONTESSA stusy of tesetaxel with a reduced dose of capecitabine versus capecitabine alone in patients with HR-positive, HER2-negative breast cancer.